Aspira Pathlab & Diagnostics Share Price Live

Aspira Pathlab & Diagnostics Limited is a public limited company incorporated in July 03rd, 1973. The Company is engaged into the business of running, owning, managing and administering Diagnostics Centers. Its principal activities consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai. During the year, the Company commenced its business activities of diagnostic center & pathology from November 2016 onwards by acquiring running business activities of 'Ankur Pathology Laboratory'. The Company issued 2943000 equity shares of Rs. 10/- each at an issue price of Rs. 17/- per share (including share premium of Rs. 7/- per share) on preferential basis to promoters & group of strategic investors not forming part of the promoter. The allotment was made on 19th November 2016 & listing & trading approval is awaited. The paid-up capital as on 31st March 2017 was 5193000 equity shares of Rs. 10/- each. The Company has changed its object clause on 10th August 2016; its present name was changed on 16th November 2016 & registered office of the company was shifted from State of West Bengal to State of Maharashtra, vide order dated 18th November, 2016 & company again shifted its registered office within the city limit of Mumbai on 17th March, 2017. During the year 2017, the Company applied to BSE Limited on 27th July 2017 under Direct Listing norms of BSE Limited for listing & trading of its securities at BSE Limited. During the year 2018-19, issued, subscribed and paid- up capital of the of the Company has increased from 5,19,30,000 to Rs. 13,69,30,000/- divided into 81,93,000 Equity Shares of Rs. 10/- each and 55,00,000 9% Non-Cumulative, Non-convertible, Non-Participating Redeemable Preference Shares of Rs. 10/- each. The Company got delisting approval from Metropolitan Stock Exchange of India Limited and Calcutta Stock Exchange Limited w.e.f. April 12th, 2018 and October 15th , 2018 respectively.